Yeah, that's all true. And I do recall JT saying that Amarin had no choice but to go to trial given Hikma's posture. Since Hikma doesn't have to spend a dime on advertising or promoting any drugs, it pays lawyers and lobbyists and counts on a heavy bias in favor of generics by Congress, states and consumers. And it probably also has developed quite a skill at massaging insurance companies and pharmacists to favor it too.
News 
Market Data 
Discover 
AI
